Phase 2 N=18 Dysport for the Treatment of OMD
Oral Dystonia · Tardive Dystonia
Primary: Mean Global Dystonia Rating Scale Score as Measured by Blinded Rater — 3.80; 3.57; 3.71 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia
Oromandibular Dystonia · Cranial Dystonia
Primary: Percent Change of the Sum of the Eyes, Mouth, Speech and Swallowing Subscores of the Burke-Fahn-Marsden (BFM) Dystonia Scale. — 12.16; 31.25 percent change
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
Phase 2 N=21 Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
Phase 3 N=108 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Spasmodic Dysphonia · Voice Tremor
Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01
Phase 2 N=53 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
Phase 3 N=516 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12) — -3.8; -4.0; -3.8…
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change
N/A N=17 Swallowing Training in Parkinson's Disease
Parkinson's Disease · Deglutition Disorders · Voice Disorders
Primary: Oropharyngeal Swallowing Score — 22.15; 21.93 Scores on a scale
Phase 2 N=10 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
Phase 3 N=134 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4. — 42.5; 42.4; 31.7; 39.9 units on a scale — p=<0.001
Phase 4 N=10 Botox for Cervical Dystonia Following EMG Mapping
Cervical Dystonia
Primary: Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)
Phase 2 N=61 A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Number of Participants With Treatment-Related Serious Adverse Events — 0; 0; 0; 0 Participants
N/A N=12 Neuromodulation Therapy for Task-Specific Dystonia
Isolated Focal Hand Dystonia
Primary: Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions — 12; 12; 11 Participants
Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…
Phase 2 N=15 An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
Dystonia, Primary
Primary: Proportion of Study Subjects Able to Titrate up to the Maximum Tolerated Dose — 6 Participants
Phase 2 N=242 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1 — 40.4; 41.5; 39.6; -10.3 Scores…
Phase 3 N=137 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
Cerebral Palsy · Neurological Conditions · Mental Retardation
Primary: Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS) — 68; 62; 7 Participants
N/A N=10 Buspirone for Functional Dysphagia
Functional Dysphagia · Ineffective Esophageal Motility
Primary: Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry — 241.9; 340.4 mm Hg
Phase 2 N=24 A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
Sialorrhoea
Primary: Saliva Secreted Rate — -6.508; -34.512; 83.695; 7.414 percentage of change from baseline
N/A N=53 Dynasplint Therapy for Trismus in Head and Neck Cancer
Trismus
Primary: Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors — 12; 12; 7; 7 participants
Phase 2 N=9 rTMS and Retraining in Focal Hand Dystonia
Focal Dystonia
Primary: Change From Baseline in Global Rating of Change at Posttest (Day 5) — 1.3; 1.2 units on a scale